Recent Advances in Adjuvant Therapy for Non–Small-Cell Lung Cancer
Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2024, v.87 no.1, pp.31-39
https://doi.org/10.4046/trd.2023.0085
Jung Seop Eom, M.D., Ph.D.
(Pusan National University School of Medicine)
Mi-Hyun Kim, M.D., Ph.D.
(Pusan National University School of Medicine)
Soo Han Kim, M.D., Ph.D.
(Department of Internal Medicine, Pusan National University School of Medicine, Busan, Biomedical Research Institute, Pusan National University Hospital, Busan, Republic of Korea)
Min Ki Lee, M.D., Ph.D.
(Pusan National University School of Medicine)
Jung,
S.
E.
M.
P.
, Mi-Hyun,
K.
M.
P.
, Soo,
H.
K.
M.
P.
, &
Min,
K.
L.
M.
P.
(2024). . Tuberculosis & Respiratory Diseases, 87(1), 31-39, https://doi.org/10.4046/trd.2023.0085
Abstract
After the successful development of targeted therapy and immunotherapy for the treatmentof advanced-stage non-small cell lung cancer (NSCLC), these innovative treatmentoptions are rapidly being applied in the adjuvant setting for early-stage NSCLC.
Some adjuvants that have recently been approved include osimertinib for epidermalgrowth factor receptor-mutated tumors and atezolizumab and pembrolizumab forselected patients with resectable NSCLC. Numerous studies on various targeted therapiesand immunotherapy with or without chemotherapy are currently ongoing in theadjuvant setting. However, several questions regarding optimal strategies for adjuvanttreatment remain unanswered. The present review summarizes the available literature,focusing on recent advances and ongoing trials with targeted therapy and immunotherapyin the adjuvant treatment of early-stage NSCLC.
- keywords
-
Carcinoma,
Non-Small-Cell Lung,
Chemotherapy,
Adjuvant,
Molecular Targeted Therapy,
Immunotherapy